NeuVax Phase 3 Trial. By my estimates, over 670 have enrolled and 38-40 control patients have had their Cancer recur. Since the interim results (70 recurrence events) have not been released yet, it means NeuVax is at least demonstrating a 25% reduction in recurrence. We only need a 30% improvement in DFS for approval.
Every week from here on out that the interim results are not released increased the DFS for NeuVax patients!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.